CD274 and neoplasm: We believe that further validation of our model with regard to tumor T cell infiltration and expression of PD-L1 will yield a patient selection strategy which will allow the application of IR and anti-PD-L1 therapy for patients with “cold” cancers, and will lead to improved outcomes.